Back to Browse Journals » Open Access Rheumatology: Research and Reviews » Volume 4

Tocilizumab in the treatment of systemic juvenile idiopathic arthritis

Authors Murakami M, Tomiita M, Nishimoto N

Published Date July 2012 Volume 2012:4 Pages 71—79

DOI http://dx.doi.org/10.2147/OARRR.S21969

Received 11 February 2012, Accepted 21 March 2012, Published 5 July 2012

Miho Murakami,1 Minako Tomiita,2,3 Norihiro Nishimoto1
1Laboratory of Immune Regulation, Wakayama Medical University, Wakayama, 2Department of Pediatrics, Graduate School of Medicine, Chiba University, Chiba, 3Department of Allergy and Rheumatology, Chiba Children's Hospital, Chiba, Japan

Abstract: Systemic juvenile idiopathic arthritis is one of the common rheumatic diseases in childhood and characterized by spiking fever, evanescent skin rash, lymphadenopathy, hepatosplenomegaly, and serositis, in addition to arthritis. Children with systemic juvenile idiopathic arthritis often show growth retardation and developmental abnormality, as well as macrophage activation syndrome, a life-threatening complication. Overproduction of interleukin-6 is pathologically responsible for the systemic inflammatory manifestations and abnormal laboratory results with systemic juvenile idiopathic arthritis. Thus, tocilizumab, a humanized antihuman interleukin-6 receptor antibody, has been developed as a therapeutic agent for the disease. A series of clinical studies have demonstrated the excellent efficacy and safety of tocilizumab for patients with active disease. Tocilizumab was approved for systemic juvenile idiopathic arthritis in Japan in 2008 and in the European Union and the United States in 2011.

Keywords: systemic juvenile idiopathic arthritis, tocilizumab, antihuman interleukin-6 receptor antibody, biologics

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Vaginal Lactobacillus: biofilm formation in vivo – clinical implications

Ventolini G

International Journal of Women's Health 2015, 7:243-247

Published Date: 16 February 2015

Unilateral transient mydriasis and ptosis after botulinum toxin injection for a cosmetic procedure

Akkaya S, Kökcen HK, Atakan T

Clinical Ophthalmology 2015, 9:313-315

Published Date: 12 February 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Synthesis and application of luminescent single CdS quantum dot encapsulated silica nanoparticles directed for precision optical bioimaging

Veeranarayanan S, Poulose AC, Mohamed MS, Nagaoka Y, Iwai S, Nakagame Y, Kashiwada S, Yoshida Y, Maekawa T, Kumar DS

International Journal of Nanomedicine 2012, 7:3769-3786

Published Date: 17 July 2012

Use of prescription paracetamol during pregnancy and risk of asthma in children: a population-based Danish cohort study

Andersen ABT, Farkas DK, Mehnert F, Ehrenstein V, Erichsen R

Clinical Epidemiology 2012, 4:33-40

Published Date: 1 February 2012

The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals

Men Y, Wang XX, Li RJ, Zhang Y, Tian W, Yao HJ, Ju RJ, Ying X, Zhou J, Li N, Zhang L, Yu Y, Lu WL

International Journal of Nanomedicine 2011, 6:3125-3137

Published Date: 2 December 2011

Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritis

Masahiko Mihara, Yoshiyuki Ohsugi, Tadamitsu Kishimoto

Open Access Rheumatology: Research and Reviews 2011, 3:19-29

Published Date: 28 February 2011